Skip to main content
Mega Genomics Limited logo

Mega Genomics Limited — Investor Relations & Filings

Ticker · 6667 HKEX Professional, scientific and technical activities
Open in API
Filings indexed 317 across all filing types
Latest filing 2026-05-05 Regulatory Filings
Country HK Hong Kong
Listing HKEX 6667

About Mega Genomics Limited

https://www.megagenomics.cn

Mega Genomics Limited operates as a genetic testing platform company focused on providing consumer genetic testing and cancer screening services. The core business involves delivering comprehensive genetic analysis solutions to the consumer market. Key product offerings include advanced sequencing packages such as Personal Whole Genome Sequencing, which analyzes over 700,000 genetic loci to assess disease risk and provide pharmacogenomic recommendations. Additionally, the company offers Adult and Children's Whole Exome Sequencing packages, which analyze over 180,000 key exome regions to evaluate risks for high-risk diseases, hereditary cancers, and complex genetic disorders, alongside personalized guidance on drug efficacy, nutrition, and fitness.

Recent filings

Filing Released Lang Actions
MONTHLY RETURN OF EQUITY ISSUER ON MOVEMENTS IN SECURITIES FOR THE MONTH ENDED 30 APRIL 2026
Regulatory Filings
2026-05-05 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement by Mega Genomics Limited under Hong Kong Exchange format, detailing the final dividend for the year ended 31 December 2025. It provides the dividend type, amount per share, important dates (ex-dividend date, record date, payment date), withholding tax, and related shareholder registration information. This matches the definition of a Notice of Dividend Amount (Code: DIV).
2026-04-28 English
FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON THURSDAY, 21 MAY 2026
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a Form of Proxy for the Annual General Meeting, which is used to solicit votes and appoint proxies for shareholder meetings. This falls under “Proxy Solicitation & Information Statement” rather than an actual report or results announcement.
2026-04-28 English
NOTICE OF ANNUAL GENERAL MEETING
Proxy Solicitation & Information Statement Classification · 1% confidence The document is a formal “Notice of Annual General Meeting” describing the date, agenda items (financial statements, director elections, dividends, share repurchase and issue mandates), proxy instructions and meeting procedures. It is clearly materials sent to shareholders to provide information ahead of voting at the AGM, matching the “Proxy Solicitation & Information Statement” category. It is not the AGM presentation itself (AGM-R), not the full annual report (10-K), and not a post-meeting voting result (DVA).
2026-04-28 English
FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025
Notice of Dividend Amount Classification · 1% confidence The document is a formal announcement titled “FINAL DIVIDEND FOR THE YEAR ENDED 31 DECEMBER 2025” containing the dividend type, amount per share, key dates (ex-dividend, record, payment), and related registration details. This matches the definition of a Notice of Dividend Amount (DIV).
2026-04-28 English
PROPOSED RE-ELECTION OF DIRECTORS, PROPOSED DECLARATION OF FINAL DIVIDEND AND PROPOSED GRANTING OF GENERAL MANDATES TO REPURCHASE SHARES AND TO ISSUE SHARES AND NOTICE OF ANNUAL GENERAL MEETING
Regulatory Filings
2026-04-28 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.